Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Karolinska Institutet | OTHER |
| Medical University of Gdansk | OTHER |
| Medical School University of Zagreb | UNKNOWN |
| Medical University of Vienna |
Not provided
Not provided
Not provided
Not provided
RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| non respondants of neo treatment | those patients with no response or partial response when administered with Chemotherapy prior to sugery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer | Other | Evaluate response to neoadjuvant treatment in advanced breast cancer |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients non-respondents vs respondents in neoadjuvant breast cancer treatment (Estimate tumor aggressiveness) | Proportion of patients who have complete response evaluating the target lesion according to Miller/Payne Grading system [Ogston et al., 2003]: 1A. Evaluation of target Tumor: G5 as pathological complete response, no tumor left; G4:more than 90% loss of tumor cells; G3: between 30-90% reduction in tumor cells; G2: loss of tumor <30%; G1: no reduction. 1B: Evaluating the lymph nodes: A: negative; B: lymph nodes with metastasis and without changes by chemotherapy; C: lymph nodes with metastasis with evidence of partial response, D: lymph nodes with changes attributed to response without residual infiltration. 1C: Using images to evaluated radiological response: Size and diameter in millimeters of the target lesion using RM and TC or PET/CT for extension analysis (lymph nodes and metastasis). | Baseline and after neoadjuvant treatment (4-6 months) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients treated with chemotherapy prior to surgery
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ana Penades-Blasco, M.Ec | Contact | +34 961245633 | ana_penades@iislafe.es |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alexander Fleming | Not yet recruiting | Buenos Aires | Argentina |
N/D
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Hacettepe University | OTHER |
| Alexander Fleming Institute | UNKNOWN |
| Ain Shams University | OTHER |
Not provided
Not provided
Not provided
| Medical University of Vienna | Not yet recruiting | Vienna | Austria |
|
| University of Zagreb School of Medicine | Not yet recruiting | Zagreb | Croatia |
|
| Ain Shams University | Not yet recruiting | Cairo | Egypt |
|
| Medical University of Gdansk | Not yet recruiting | Gdansk | Poland |
|
| Hospital Universitario y Politécnico La Fe de Valencia | Recruiting | Valencia | 46026 | Spain |
|
| Karolinska Institute | Not yet recruiting | Stockholm | Sweden |
|
| Hacettepe University | Not yet recruiting | Ankara | Turkey (Türkiye) |
|
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided